SGLT-2抑制剂与癌症报告风险:VigiBase不成比例分析
基于WHO VigiBase 2014–2023年数据,比较SGLT-2抑制剂与GLP-1类似物及DPP-4抑制剂的癌症报告不成比例分析,共644例SGLT-2i相关癌症报告。结果显示膀胱癌(ROR 4.46,95%CI 3.23-6.17)和肾癌(ROR 1.84,95%CI 1.25-2.69)报告风险升高,其他癌种未见升高。
要点
- 使用SGLT-2抑制剂的患者中,膀胱癌和肾癌的报告风险显著升高。
- 其他癌症亚型未见报告风险升高。
- 该信号需进一步长期观察性研究澄清。
核心结论
- SGLT-2抑制剂与膀胱癌和肾癌的报告风险升高相关。
- 该研究为假设生成性分析,需长期观察性研究进一步澄清信号。
研究设计与样本
- 基于WHO VigiBase 2014–2023年数据的不成比例分析。
- 比较SGLT-2抑制剂与GLP-1类似物及DPP-4抑制剂的癌症报告风险。
主要发现
- SGLT-2i相关癌症报告644例,其中男性427例(66.3%),平均年龄66.5±9.7岁。
- 膀胱癌报告比值比ROR 4.46(95%CI 3.23-6.17)。
- 肾癌报告比值比ROR 1.84(95%CI 1.25-2.69)。
- 其他癌症亚型未见报告风险升高。
临床怎么用
- 临床使用SGLT-2抑制剂时,应关注膀胱癌和肾癌相关症状。
- 对于有膀胱癌或肾癌病史的患者,处方SGLT-2抑制剂需权衡利弊。
局限性
- 不成比例分析为假设生成性研究,不能确立因果关系。
- 研究仅基于自发报告数据,可能存在报告偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Use of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) has significantly increased due to their cardiovascular benefits. Whether SGLT-2is increase risk of cancer has been of concern since first clinical trials, but this question remains unclear because of methodological limitations in previous studies. METHODS: We conducted a disproportionality analysis using Vigibase® between 2014 and 2023 to estimate the association between SGLT-2i use and the risk of reporting of different subtypes of cancers, compared with glucagon like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors. RESULTS: Among 644 reported cases of cancer associated with SGLT-2i use, 427 (66.3%) were male, with a mean age of 66.5 ± 9.7 years. Sodium-glucose cotransporter 2 inhibitors showed increased reporting odds ratio for bladder cancer (ROR 4.46, 95% CI 3.23-6.17) and kidney cancer (ROR 1.84, 95% CI 1.25-2.69), but not for all other cancer subtypes. CONCLUSION: In this disproportionality analysis with a hypothesis-generating approach, SGLT-2is are associated with an increased risk of reporting bladder and kidney cancer. There is a need of an urgent clarification of this signal with further long-term observational studies.
引用
- Gautier P, Elbaz M, Bouisset F, et al. Investigating Risk of Cancer with Sodium-Glucose Cotransporter 2 Inhibitors: A Disproportionality Analysis in the WHO Global Pharmacovigilance Database Vigibase®. Drug Saf. 2025. PMID: 40232585. doi:10.1007/s40264-025-01546-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。